Paul Sekhri joins Topas Therapeutics as Chairman of the Board
Hamburg, Germany, April 4, 2017
Topas Therapeutics GmbH ("Topas"), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately.
Paul Sekhri is currently CEO and President of the US based company Lycera Corporation (New York / NY & Ann Arbor / MI). Mr Sekhri has gained a wealth of experience in pharma, biotech and in the investment community - both in Europe and the US - by serving in various leading management positions in e.g. Sanofi, Teva, Novartis, Ariad and the TPG Capital group (TPG Biotech).